Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of epithelial ovarian cancer among women with benign ovarian tumors: a follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Regular physical activity and mammographic density: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Residential traffic noise and mammographic breast density in the Diet, Cancer, and Health cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters.

METHODS: We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. From Danish nationwide registries and medical records, we retrieved complete prescription histories and prostate cancer occurrence and characteristics. Cox regression was used to estimate hazard ratios (HRs) for prostate cancer associated with low-dose aspirin or nonaspirin NSAID use, overall and by clinical characteristics, anthropometric measures, and lifestyle factors.

RESULTS: We identified 1,927 prostate cancer cases during a median follow-up of 17.0 years. Low-dose aspirin use was not associated with overall prostate cancer risk, but a reduced HR for nonaggressive prostate cancer (high use [≥ 1,825 tablets]: 0.79; 95% confidence interval (CI) 0.60-1.04) and an increased HR for aggressive disease (high use: 1.27; 95% CI 1.00-1.61) was observed with low-dose aspirin use. Long-term, high-intensity use (≥ 10 years with ≥ 0.25 defined daily doses/day) of nonaspirin NSAIDs was associated with an increased HR for prostate cancer (1.35, 95% CI 0.99-1.84), confined to localized and nonaggressive disease. No consistent variation in HRs was seen in analyses stratified by height, body mass index, smoking, and alcohol use.

CONCLUSION: Low-dose aspirin or other NSAID use was not associated with reduced prostate cancer risk, neither overall nor according to anthropometric measures, smoking, or alcohol use. The variation according to outcome characteristics warrants further investigation.

Original languageEnglish
JournalCancer causes & control : CCC
Volume31
Issue number2
Pages (from-to)139-151
ISSN0957-5243
DOIs
Publication statusPublished - Feb 2020

    Research areas

  • Aspirin, Cohort study, Epidemiology, Nonsteroidal anti-inflammatory drugs, Prostate neoplasms, Risk

ID: 58622777